Early-time-point ¹⁸F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy

1. Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, et al; CheckMate 067 Investigators. Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2024; 392: 11-22. doi: 10.1056/NEJMoa2407417 Wolchok JD Chiarion-Sileni V Rutkowski P Cowey CL Schadendorf D Wagstaff J CheckMate 067 Investigators. Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma . N Engl J Med 2024 ; 392 : 11 – 22 . doi: 10.1056/NEJMoa2407417 Open DOISearch in Google Scholar

2. Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol 2024; 35: 1191-9. doi: 10.1016/j.annonc.2024.08.2330 Long GV Carlino MS McNeil C Ribas A Gaudy-Marqueste C Schachter J Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study . Ann Oncol 2024 ; 35 : 1191 – 9 . doi: 10.1016/j.annonc.2024.08.2330 Open DOISearch in Google Scholar

3. Pires da Silva I, Ahmed T, McQuade JL, Nebhan CA, Park JJ, Versluis JM, et al. Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma. J Clin Oncol 2022; 40: 1068-80. doi: 10.1200/JCO.21.01701 Pires da Silva I Ahmed T McQuade JL Nebhan CA Park JJ Versluis JM Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma . J Clin Oncol 2022 ; 40 : 1068 – 80 . doi: 10.1200/JCO.21.01701 Open DOISearch in Google Scholar

4. Schadendorf D, Livingstone E, Zimmer L. Treatment in metastatic mela-noma-time to rethink. Ann Oncol 2019; 30: 501-3. doi: 10.1093/annonc/mdz050 Schadendorf D Livingstone E Zimmer L. Treatment in metastatic mela-noma-time to rethink . Ann Oncol 2019 ; 30 : 501 – 3 . doi: 10.1093/annonc/mdz050 Open DOISearch in Google Scholar

5. Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab-real-world experience. Radiol Oncol 2020; 54: 119-27. doi: 10.2478/raon-2020-0003. Hribernik N Boc M Ocvirk J Knez-Arbeiter J Mesti T Ignjatovic M Retrospective analysis of treatment-naive Slovenian patients with metastat-ic melanoma treated with pembrolizumab-real-world experience . Radiol Oncol 2020 ; 54 : 119 – 27 . doi: 10.2478/raon-2020-0003. Open DOISearch in Google Scholar

6. Wan G, Chen W, Khattab S, Roster K, Nguyen N, Yan B, et al. Multiorgan immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study. Lancet Oncol 2024; 25: 1053-69. doi: 10.1016/S1470-2045(24)00278-X Wan G Chen W Khattab S Roster K Nguyen N Yan B Multiorgan immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study . Lancet Oncol 2024 ; 25 : 1053 – 69 . doi: 10.1016/S1470-2045(24)00278-X Open DOISearch in Google Scholar

7. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, et al. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F] FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 2022; 49: 2323-41. doi: 10.1007/s00259-022-05780-2 Lopci E Hicks RJ Dimitrakopoulou-Strauss A Dercle L Iravani A Seban RD Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F] FDG PET/CT imaging during im-munomodulatory treatments in patients with solid tumors version 1.0 . Eur J Nucl Med Mol Imaging 2022 ; 49 : 2323 – 41 . doi: 10.1007/s00259-022-05780-2 Open DOISearch in Google Scholar

8. Dimitriou F, Lo SN, Tan AC, Emmett L, Kapoor R, Carlino MS, et al. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol 2022; 33: 99-106. doi: 10.1016/j.annonc.2021.10.003 Dimitriou F Lo SN Tan AC Emmett L Kapoor R Carlino MS FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic mela-noma . Ann Oncol 2022 ; 33 : 99 – 106 . doi: 10.1016/j.annonc.2021.10.003 Open DOISearch in Google Scholar

9. Santo G, Cucè M, Restuccia A, Del Giudice T, Tassone P, Cicone F, et al. Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications. Cancer Imaging 2024; 24: 125. doi: 10.1186/s40644-024-00774-9 Santo G Cucè M Restuccia A Del Giudice T Tassone P Cicone F Immune-related [18F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications . Cancer Imaging 2024 ; 24 : 125 . doi: 10.1186/s40644-024-00774-9 Open DOISearch in Google Scholar

10. Hribernik N, Strasek K, Huff DT, Studen A, Zevnik K, Skalic K, et al. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study. Radiol Oncol 2024; 58: 335-47. doi: 10.2478/raon-2024-0045 Hribernik N Strasek K Huff DT Studen A Zevnik K Skalic K Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study . Radiol Oncol 2024 ; 58 : 335 – 47 . doi: 10.2478/raon-2024-0045 Open DOISearch in Google Scholar

11. Hribernik N, Huff DT, Studen A, Zevnik K, Klaneček Ž, Emamekhoo H, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging 2022; 49: 1857-69. doi: 10.1007/s00259-021-05650-3 Hribernik N Huff DT Studen A Zevnik K Klaneček Ž Emamekhoo H Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study . Eur J Nucl Med Mol Imaging 2022 ; 49 : 1857 – 69 . doi: 10.1007/s00259-021-05650-3 Open DOISearch in Google Scholar

12. Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med 2017; 58: 1421-8. doi: 10.2967/jnumed.116.188839 Cho SY Lipson EJ Im HJ Rowe SP Gonzalez EM Blackford A Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma . J Nucl Med 2017 ; 58 : 1421 – 8 . doi: 10.2967/jnumed.116.188839 Open DOISearch in Google Scholar

13. National Cancer Institute (NCI). NCI Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.2021. [cited 2023 Oct 23]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf National Cancer Institute (NCI) . NCI Common Terminology Criteria for Adverse Events (CTCAE) . Version 5.0.2021. [ cited 2023 Oct 23 ]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5×11.pdf Search in Google Scholar

14. Nelson EK, Piehler B, Eckels J, Rauch A, Bellew M, Hussey P, et al. LabKey Server: an open source platform for scientific data integration, analysis and collaboration. BMC Bioinformatics 2011; 12: 71. doi: 10.1186/1471-2105-12-71 Nelson EK Piehler B Eckels J Rauch A Bellew M Hussey P LabKey Server: an open source platform for scientific data integration, analysis and collaboration . BMC Bioinformatics 2011 ; 12 : 71 . doi: 10.1186/1471-2105-12-71 Open DOISearch in Google Scholar

15. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. doi: 10.1016/s0959-8049(99)00229-4 Young H Baum R Cremerius U Herholz K Hoekstra O Lammertsma AA Measurement of clinical and subclinical tumor response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group . Eur J Cancer 1999 ; 35 : 1773 – 82 . doi: 10.1016/s0959-8049(99)00229-4 Open DOISearch in Google Scholar

16. Anderson TM, Chang BH, Huang AC, Xu X, Yoon D, Shang CG, et al. FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma. Clin Cancer Res 2024; 30: 1758-67. doi: 10.1158/1078-0432.CCR-23-2390 Anderson TM Chang BH Huang AC Xu X Yoon D Shang CG FDG PET/CT imaging 1 week after a single dose of pembrolizumab predicts treatment response in patients with advanced melanoma . Clin Cancer Res 2024 ; 30 : 1758 – 67 . doi: 10.1158/1078-0432.CCR-23-2390 Open DOISearch in Google Scholar

17. Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, van den Heuvel NMJ, Saw RPM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 2022; 28: 1178-88. doi: 10.1038/s41591-022-01851-x Reijers ILM Menzies AM van Akkooi ACJ Versluis JM van den Heuvel NMJ Saw RPM Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial . Nat Med 2022 ; 28 : 1178 – 88 . doi: 10.1038/s41591-022-01851-x Open DOISearch in Google Scholar

18. Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med 2024; 391: 1696-708. doi: 10.1056/NEJMoa2402604 Blank CU Lucas MW Scolyer RA van de Wiel BA Menzies AM Lopez-Yurda M Neoadjuvant nivolumab and ipilimumab in resectable stage III mel-anoma . N Engl J Med 2024 ; 391 : 1696 – 708 . doi: 10.1056/NEJMoa2402604 Open DOISearch in Google Scholar

19. Taghanaki SA, Zheng Y, Kevin Zhou S, Georgescu B, Sharma P, Xu D, et al. Combo loss: handling input and output imbalance in multiorgan segmentation. Comput Med Imaging Graph 2019; 75: 24-33. doi: 10.1016/j.comp-medimag.2019.04.005 Taghanaki SA Zheng Y Kevin Zhou S Georgescu B Sharma P Xu D Combo loss: handling input and output imbalance in multiorgan segmenta-tion . Comput Med Imaging Graph 2019 ; 75 : 24 – 33 . doi: 10.1016/j.comp-medimag.2019.04.005 Open DOISearch in Google Scholar

20. Huff DT, Ferjancic P, Namías M, Emamekhoo H, Perlman SB, Jeraj R. Image intensity histograms as imaging biomarkers: application to immune-related colitis. Biomed Phys Eng Express 2021; 7: 065019. doi: 10.1088/2057-1976/ac27c3 Huff DT Ferjancic P Namías M Emamekhoo H Perlman SB Jeraj R. Image intensity histograms as imaging biomarkers: application to immune-related colitis . Biomed Phys Eng Express 2021 ; 7 : 065019 . doi: 10.1088/2057-1976/ac27c3 Open DOISearch in Google Scholar

21. Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nat Cancer 2024; 5: 557-71. doi: 10.1038/s43018-024-00730-3 Suijkerbuijk KPM van Eijs MJM van Wijk F Eggermont AMM. Clinical and translational attributes of immune-related adverse events . Nat Cancer 2024 ; 5 : 557 – 71 . doi: 10.1038/s43018-024-00730-3 Open DOISearch in Google Scholar

22. Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol 2023; 7: 41. doi: 10.1038/s41698-023-00380-1 Verheijden RJ van Eijs MJM May AM van Wijk F Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance . NPJ Precis Oncol 2023 ; 7 : 41 . doi: 10.1038/s41698-023-00380-1 Open DOISearch in Google Scholar

23. Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. ¹⁸F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 2020; 20: 36. doi: 10.1186/s40644-020-00313-2 Wong A Callahan J Keyaerts M Neyns B Mangana J Aberle S ¹⁸F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipili-mumab in patients with metastatic melanoma . Cancer Imaging 2020 ; 20 : 36 . doi: 10.1186/s40644-020-00313-2 Open DOISearch in Google Scholar

24. Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021; 48: 428-48. doi: 10.1007/s00259-020-04967-9 Ayati N Sadeghi R Kiamanesh Z Lee ST Zakavi SR Scott AM. The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis . Eur J Nucl Med Mol Imaging 2021 ; 48 : 428 – 48 . doi: 10.1007/s00259-020-04967-9 Open DOISearch in Google Scholar

25. Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, et al. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST. Jpn J Radiol 2022; 40: 75-85. doi: 10.1007/s11604-021-01174-w Kitajima K Watabe T Nakajo M Ishibashi M Daisaki H Soeda F Tumor response evaluation in patients with malignant melanoma undergo-ing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST . Jpn J Radiol 2022 ; 40 : 75 – 85 . doi: 10.1007/s11604-021-01174-w Open DOISearch in Google Scholar

26. Iravani A, Hicks RJ. Imaging the cancer immune environment and its response to pharmacologic intervention, Part 1: The role of ¹⁸F-FDG PET/CT. J Nucl Med 2020; 61: 943-50. doi: 10.2967/jnumed.119.234278 Iravani A Hicks RJ. Imaging the cancer immune environment and its re-sponse to pharmacologic intervention, Part 1: The role of ¹⁸F-FDG PET/CT . J Nucl Med 2020 ; 61 : 943 – 50 . doi: 10.2967/jnumed.119.234278 Open DOISearch in Google Scholar

27. Shreve JT, Khanani SA, Haddad TC. Artificial intelligence in oncology: current capabilities, future opportunities, and ethical considerations. Am Soc Clin Oncol Educ Book 2022; 42: 1-10. doi: 10.1200/EDBK_350652 Shreve JT Khanani SA Haddad TC. Artificial intelligence in oncology: current capabilities, future opportunities, and ethical considerations . Am Soc Clin Oncol Educ Book 2022 ; 42 : 1 – 10 . doi: 10.1200/EDBK_350652 Open DOISearch in Google Scholar

28. de Groot DJA, Lub-de Hooge MN, van Meerten T, Brouwers AH, de Vries EGE. Facts and hopes for PET imaging-derived immunotherapy biomarkers. Clin Cancer Res 2024; 30: 5252-9. doi: 10.1158/1078-0432.CCR-24-1427 de Groot DJA Lub-de Hooge MN van Meerten T Brouwers AH de Vries EGE. Facts and hopes for PET imaging-derived immunotherapy biomarkers . Clin Cancer Res 2024 ; 30 : 5252 – 9 . doi: 10.1158/1078-0432.CCR-24-1427 Open DOISearch in Google Scholar